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We report 15 imported louse-borne relapsing fever 
(LBRF) cases in refugees in Bavaria, Germany. One 
patient died. Epidemiological findings confirmed that 
all were young males from the Horn of Africa (12 from 
Somalia), who had similar migration routes converg-
ing in Sudan continuing through Libya and Italy. The 
majority likely acquired their infection during migra-
tion. Healthcare workers should be aware of LBRF in 
refugees passing through north Africa to ensure cor-
rect treatment and preventive measures.
From July 2015 until October 2015, Louse-borne relaps-
ing fever (LBRF) was diagnosed in 15 refugees origi-
nating from the Horn of Africa and arriving in Bavaria, 
southern Germany, presenting with fever. The main 
travel route included Sudan, Libya and Italy. In this 
rapid communication, microbiological confirmation, 
simple first-line epidemiologic assessment and pre-
ventive control measures in relation to these cases are 
described.
Case investigation
In all cases, a preliminary diagnosis was established 
by clinicians based on clinical symptoms and vis-
ible spirochetes in Giemsa stained blood films The 
German National Reference Centre (NRC) for Borrelia in 
Oberschleißheim was contacted directly by clinicians 
for confirmation. Microbiological confirmation of LBRF 
from EDTA blood included: Dark field microscopy (Leitz 
Dialux 20 microscope, Leitz, Germany, objective 40, 
occular 10) and PCR targeting 16S rRNA, flab, and glpQ 
followed by sequencing [1-3].
Blood samples were used for in vitro cultures in modi-
fied Kelly-Pettenkofer (MKP) medium [4]. A case was 
regarded as confirmed when sequencing revealed B. 
recurrentis.
Because of a potentially high public health relevance, 
i.e. establishment of local foci of louse-borne trans-
mission in refugee facilities, treating hospitals and 
spill over to the local population, epidemiological 
data to establish preventive measures are of utmost 
importance. Therefore a standardised questionnaire 
for case investigations and interviews was developed, 
distributed and evaluated by the Bavarian Task-Force 
Infectiology and International Health Regulations. 
Interviews were performed by public health physicians 
of local public health agencies as part of the official 
investigation of infectious diseases of public health 
concern according to the German federal law, and with 
the help of an interpreter. The interviews were per-
formed in a hospital setting and by taking into consid-
eration potential emotional and psychological trauma 
of refugees. Anonymised data were used for further 
analysis. When interviewing was not possible, informa-
tion was retrieved from medical records, if available. A 
leaflet informing about clinical presentation, epidemi-
ology, diagnostics as well as preventive control meas-
ures, was developed and sent to clinicians and public 
health authorities to raise general awareness.
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Results of the investigations
Of the 15 suspected LBRF cases submitted to the NRC, 
14 were confirmed as being caused by B. recurrentis. In 
one case, spirochetes were visible on Giemsa stained 
blood films, but insufficient material was provided for 
molecular diagnosis. However, the epidemiological 
data suggest LBRF. Details of diagnostic results are 
shown in Table 1.
Table 2 gives an overview of basic epidemiological 
information including disease onset and travel history.
All 15 cases were males with a median age of 20 years 
(range 15 to 33 years) and all originated from northeast 
Africa: 12 from Somalia, two from Eritrea and one from 
Ethiopia.
Information about migration route was available from 
12 patients (Table 2). A comprehensive migration route 
was indicated by seven patients, all from Somalia: 
From Somalia via Ethiopia to Sudan (n=4) or via Kenya, 
South Sudan to Sudan (n=3), all went further to Libya 
and then via Italy and transit through Austria to Bavaria 
(Figure 1).
Four patients reported a stay in Italy between two and 
14 days, respectively. Six patients reported chang-
ing of clothes upon arrival in a refugee camp in Italy. 
Five patients reported a longer stay in Libya (ranging 
from 17 days to nine months). Three of them reported 
to have been exposed to very poor, overcrowded living 
conditions during transit in Libya. They also reported of 
fellow refugees with pruritus and infestation with lice. 
Travel duration of individuals ranged from eight weeks 
to one year. In eight of the 10 patients with available 
information, onset of symptoms was before arrival in 
Munich. Only two reported onset of symptoms after 
arrival (Figure 2). Nine refugees reported that they 
had already been accommodated in a refugee facility 
in Bavaria, four were directly hospitalised upon arrival 
in Munich, and for two patients information was not 
specified. Duration of stay in a refugee 
Table 3 gives an overview over reported symptoms. 
All patients were hospitalised and received antibi-
otic treatment with doxycyline. One of the 15 patients 
died of multi-organ failure after initiation of antibiotic 
therapy despite intensive care treatment. Although 
Jarisch-Herxheimer reaction was not systematically 
Figure 1
Travel routes of cases of imported louse-borne relapsing 
fever in refugees from northeast Africa to Bavaria, 










Common route of travel for all cases
Three cases 
Map obtained from d-maps (http://www.d-maps.com/carte.
php?num_car=18215&lang=en).
a Comprehensive information on migration routes was available for 
seven of the 15 cases.
ER: Eritrea; ET: Ethiopia; IT: Italy; KE: Kenya; LY: Libya; SD: Sudan; 
SO: Somalia; SS: South Sudan.
Figure 2
Duration from onset of symptoms to and since arrival in 
Bavaria for cases of imported louse-borne relapsing fever 






































Negative numbers represent an onset of symptoms before arrival 
in Bavaria whereas positive numbers represent an onset of 
symptoms after arrival in Bavaria.
NR: not reported.
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investigated, all 10 patients with available information 
were reported to have had Jarisch-Herxheimer reaction 
to antibiotic treatment.
Discussion
Historically, LBRF was observed as large outbreaks 
affecting millions of people during wars, civil unrest 
or under extreme poverty [5,6]. Notably, mortality can 
still be high, above 30% for untreated cases and 2% 
to 6% for those receiving appropriate treatment [7]. 
Endemic areas of LBRF were known to exist in north-
east Africa in Ethiopia and in neighbouring countries, 
including Eritrea, Somalia and Southern Sudan, and 
are suspected in the Peruvian Andes and the Himalayas 
[5,8-10]. However, according to recent research, it is 
believed that endemic LBRF hot spots only persist in 
Ethiopia, occasionally spilling to neighbouring coun-
tries [7,11,12].
In Germany, only three cases of imported LBRF were 
reported since 1999 [13-15]. Imported LBRF among 
refugees from endemic areas entering the European 
Union (EU) is not unexpected considering the massive 
increase in migration of refugees from northeast Africa 
[16,17]. According to official data, Eritrea is one of the 
main countries of origin of refugees in Bavaria (652 in 
January–June 2015) [18]. In Germany, 3,284 refugees 
from Somalia were seeking asylum in 2015 until the 
month of August [19].
Our data suggest that young male refugees originat-
ing from the Horn of Africa may be at particular risk of 
acquiring LBRF. Accordingly, imported LBRF was found 
in three young male refugees from Eritrea only recently 
in Switzerland and the Netherlands [20,21].
Onset of symptoms in the eight of 10 patients with 
available information in our series was just before or 
shortly after arrival in Bavaria. None of them reported 
recurring fever episodes. Hence, we assume an early 
stage of disease in them. Considering a mean incuba-
tion period of four to eight days (range 2 to 15 days) 
[22] and a duration of migration ranging from eight 
weeks to one year, infection in these eight patients has 
most likely been acquired towards the end of their jour-
neys, hence in Libya or Italy. The patients could only 
provide rough estimates of the exact travel duration 
and accordingly very limited information on when they 
entered or left transit countries. Therefore, the exact 
place of infection remains unclear. However, especially 
Case
Microscopy Sequencing
Darkfield Giemsa 16S rDNA glpQ flab 
1a  Positive Positive  Positive Positive   Positive
2 Negative  Positive  Positive Positive   Positive
3a  Positive  Positive  Positive Positive Positive
4a  Positive  Positive  Positive Positive Positive
5a  Positive  Positive  Positive   Positive Negative
6 NA  Positive NP NP NP
7a  Positive  Positive  Positive Positive Positive
8 Negative  Positive  Positive Negative Positive
9 Negative  Positive  Positive Positive Negative
10 Negative  Positive  Positive IP Positive
11  Positive  Positive  Positive Positive Positive
12  Positive  Positive  Positive Positive Positive
13a  Positive  Positive  Positive Positive Positive
14  Positive  Positive  Positive IP Positive
15  Positive  Positive  Positive Positive Positive
Table 1
Diagnostic results of cases of imported louse-borne 
relapsing fever in refugees from northeast Africa to 
Bavaria, Germany, July–October 2015 (n=15)
a Successful cultivation.
IP: in process; NA: not available; NP: no material provided.















From SO via LY 3





5 months–1 year 1
NR 7
Onset of symptoms
Before arrival in Bavaria 8
After arrival in Bavaria 2
NR 5





Descriptive epidemiological information on cases of 
imported louse-borne relapsing fever in refugees from 
northeast Africa to Bavaria, Germany, July–October 2015 
(n=15)
ER: Eritrea; ET: Ethiopia; IT: Italy; KE: Kenya; LY: Libya; NR: not 
reported; SD: Sudan; SO: Somalia; SS: South Sudan.
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for five cases who reported onset of symptoms within 
days before or shortly after arrival, an infection not 
only in Libya but also in Italy or while crossing the 
Mediterranean Sea is possible. Two patients reported 
an onset of symptoms 20 and 36 days, respectively, 
before arrival in Germany. The patient with the longer 
duration of symptoms reported that he had travelled 
through Ethiopia. For the two patients and those with 
insufficient information regarding the travel route, an 
infection while travelling through the known endemic 
hot spot Ethiopia or Sudan could not be ruled out. 
However, considering incubation time, onset of symp-
toms, travel duration and the fact that six patients did 
report no symptoms when leaving their country of ori-
gin, we assume that LBRF was acquired later, at places 
along migration routes with established endemic LBRF 
foci.
We are aware that the data retrieved during interviews 
are limited by recall bias and language problems. In 
particular, the lack of exact data on duration of the jour-
neys remains problematic when estimating the prob-
able place of infection. Indeed, we conclude that LBRF 
has already been introduced in places along migration 
routes, most likely in Libya, on refugee boats crossing 
the Mediterranean Sea and perhaps in Italy. Looking at 
specified migration routes, the introduction of LBRF to 
these places is possible by refugees who acquired the 
disease in Ethiopia.
Interestingly, not a single LBRF infection was found in 
refugees originating from other African regions though 
their migration routes partially overlap [23].
The current assessment provides no evidence that 
transmission occurred while the individuals were in 
Bavaria. However, public health measures were imple-
mented to prevent further transmission, since nine of 
the 15 refugees already stayed in a refugee facility in 
Bavaria before they were diagnosed. As primary pre-
ventive public health measure, basic hygiene was 
recommended which includes changing, washing and 
drying of clothes and bedding at ≥ 60 °C on a regular 
basis for infected individuals and close contacts [24]. 
Additionally, active contact tracing of cases in terms of 
symptoms, infestation with body lice and assessment 
of living conditions was recommended as a further pre-
caution. Furthermore, it was recommended to actively 
offer washing of clothes upon arrival, especially, but 
not limited to refugees from endemic areas. As the 
detection of infestation with lice might generally not 
be very reliable (in our assessment only reported in 




















1 No No No NR NR No No NR Yes Yes
2 NR Yes NR NR NR NR NR NR Yes f NR
3 NR Yes NR NR NR NR NR NR Yes f NR
4 No Yes Several episodes NR No Yes
a Yesb No ICU Yes
5 No Yes No Yes Yes Yesc No Yes Yes Yes
6 No Yes No Yes Yes No No No Yes Yes
7 No Yes No Yes Yes No Yes No Yes Yes
8 No Yes No Yes Yes No NR No Yes Yes
9 NR Yes NR NR NR NR NR NR Yes f NR
10 NR Yes NR NR NR NR NR NR Yes f NR
11 NR Yes NR Yes NR Yes c,d Yes Yes Yes Yes
12 NR Yes NR Yes NR No NR Yes Yes Yes
13 NR Yes NR NR NR NR NR NR Yes Noe
14 NR Yes No Yes yes No Yes No Yes Yes
15 NR Yes No Yes yes Yesc No Yes Yes Yes
Table 3
Reported symptoms and outcome in louse-borne relapsing fever in refugees from northeast Africa to Bavaria, Germany, 
July– October 2015
ICU: intensive care unit; NR: not reported.
a Abdominal pain.




f Lost to follow-up.
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To raise awareness in the medical and public health 
communities, public health authorities and physicians 
throughout Bavaria have been informed about clinical 
symptoms and general epidemiology of LBRF. Leaflets 
describing LBRF and recommended public health meas-
ures were distributed nationally. Public health institu-
tions in Libya and Italy were already informed by the 
Robert-Koch-Institute (RKI) (personal communication, 
Dr H Wilking, RKI, September 2015) as well as further 
organisations such as the World Health Organization 
(WHO) and Médecins Sans Frontières (MSF).
Conclusions
Young male refugees originating from the Horn of 
Africa seem to be at major risk for acquiring LBRF. 
LBRF most likely was not acquired in their countries of 
origin but on migration routes, most likely in Libya or 
Italy. No evidence for transmission of LBRF infections 
in Bavaria was found. However meaningful preventive 
control measures were implemented. The findings of 
our investigation should be strengthened by further 
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